Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide in pediatric functional constipation and IBS-C
NCT04166058Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Primary completion
- Jun 2025
- Modality
- Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of linaclotide in functional constipation (FC) and irritable bowel syndrome (IBS) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Treatment-Emergent Adverse Events at 52 weeks. Started Nov 2019; status: completed.
02
Drugs
linaclotide
03
Conditions
functional constipation (FC)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT04166058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166058.